Regulatory adaptive status in determining the effectivenessof bisoprololum and sotalolum in patients with hypertensive disease and ventricular arrhythmias
Aim. Compare the effectiveness of treatment with bisoprololum or sotalolum in patients with hypertensive disease (HD) and ventricular arrhythmias (VA) taking into account quantitative evaluation of the regulatory adaptive status (RAS).Materials and methods. 48 patients with HD of stages II-III and V...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IP Morozov P.V.
2016-03-01
|
| Series: | Системные гипертензии |
| Subjects: | |
| Online Access: | https://syst-hypertension.ru/2075-082X/article/viewFile/29116/pdf |
| Summary: | Aim. Compare the effectiveness of treatment with bisoprololum or sotalolum in patients with hypertensive disease (HD) and ventricular arrhythmias (VA) taking into account quantitative evaluation of the regulatory adaptive status (RAS).Materials and methods. 48 patients with HD of stages II-III and VA of grade I-IV based on the В.Lown grading system, II-III groups based on J.Bigger grading system took part in the research, they were randomized into two groups for treatment with bisoprololum (6.2±1.7 mg/day) or sotalolum (159.1±47.4 mg/day). As part of combination therapy, patients were administered lisinoprilum (12.8±4.2 mg/day and 13.7±4.5 mg/day), acetylsalicylic acid when required (93.1±19.0 and 95.0±16.2 mg/day), atorvastatinum (15.9±4.6 mg/day and 15.6±4.9 mg/day), respectively. Initially and 6 months after therapy, the following was done: quantitative assessment of RAS (by cardio-respiratory synchronism test), echocardiography, triplex scanning of brachiocephalic arteries, treadmill test, six-minute walk test, all-day monitoring of blood pressure and electrocardiogram, subjective assessment of quality of life.Results. Both drug regimens comparably improved structural and functional condition of the heart, increased exercise tolerance, controlled arterial hypertension, effectively suppressed ventricular arrhythmia, improved the quality of life. At the same time, the use of sotalolum decreased the RAS to a lesser degree than the use of bisoprololum.Conclusion. In patients with HD of stages II-III and VA the use of sotalolum as part of combination therapy may be preferable to bisoprololum due to its less negative impact on the RAS. |
|---|---|
| ISSN: | 2075-082X 2542-2189 |